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during Adult Cardiac Surgery: A 
Meta analysis
Chenghui Zhou1, Heerajnarain Bulluck2,3,4, Nengxin Fang1, Lihuan Li1 & Derek J. 
Hausenloy2,3,4,5
We aimed to conduct an up-to-date meta-analysis to comprehensively assess the renoprotective effect 
of remote ischemic preconditioning (RIPC) in patients undergoing adult cardiac surgery. 21 randomized 
controlled trials (RCTs) with a total of 6302 patients were selected and identified. Compared with 
controls, RIPC significantly reduced the incidence of acute kidney injury (AKI) [odds ratio (OR) = 0.79; 
P = 0.02; I2 = 38%], and in particular, AKI stage I (OR = 0.65; P = 0.01; I2 = 55%). RIPC significantly 
shortened mechanical ventilation (MV) duration [weighted mean difference (WMD) = −0.79 hours; 
P = 0.002; I2 = 53%), and reduced intensive care unit (ICU) stay (WMD = −0.23 days; P = 0.07; I2 = 96%). 
Univariate meta-regression analyses showed that the major sources of heterogeneity for AKI stage 
I were age (coefficient = 0.06; P = 0.01; adjusted R2 = 0.86) and proportion of complex surgery 
(coefficient = 0.02; P = 0.03; adjusted R2 = 0.81). Subsequent multivariate regression and subgroup 
analyses also confirmed these results. The present meta-analysis suggests that RIPC reduces the 
incidence of AKI in adults undergoing cardiac surgery and this benefit was more pronounced in younger 
patients undergoing non-complex cardiac surgery. RIPC may also shorten MV duration and ICU stay. 
Future RCTs tailored for those most likely to benefit from RIPC warrants further investigation.
Acute kidney injury (AKI) occurs in up to 30%1 of patients undergoing adult cardiac surgery, and it is associated 
with prolonged respiratory support and intensive care unit (ICU) stay, may increase the risk of short-term and 
long-term death2–4, especially in those requiring renal replacement therapy (RRT)5. Moreover, with increasing 
morbidity (such as advanced age, diabetes mellitus, and complex surgical procedures) in this population, postop-
erative AKI is becoming an important issue in adult patients undergoing cardiac surgery6, 7.
Remote ischemic preconditioning (RIPC) is a noninvasive, feasible and low-cost approach elicited by several 
brief episodes of ischemia and reperfusion (I/R) in a remote organ (a limb using a blood pressure cuff in this 
study) to offer protection from subsequent ischemic injury8. RIPC has proven to be beneficial to protect against 
I/R injury of various organs9 including the kidney10–13 in numerous animal studies. In human, RIPC has also been 
shown to prevent reperfusion-induced endothelial dysfunction14–16, and offers a promising strategy for reducing 
the burden associated with AKI in patients undergoing cardiac surgery.
Several randomized controlled trials (RCTs)17–22 have reported on the impact of RIPC on preventing AKI, 
but the results are mixed. Recently, several striking large-scale RCTs23–27 with mixed findings have added to the 
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available evidence for the renoprotective effect of RIPC in adult cardiac surgery. Therefore, we aimed to conduct 
an up-to-date meta-analysis to comprehensively evaluate the effect of RIPC on the incidence of AKI and identify 
the related potential influential factors in adults undergoing cardiac surgery.
Results
Study characteristics. Figure 1 shows the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) flow chart for the RCTs screening and selection process for inclusion in this study. 21 
RCTs17–37 with a total of 6302 patients met the inclusion criteria. 6 RCTs were conducted for isolated coro-
nary artery bypass graft (CABG)17, 22, 28–31, 5 RCTs were done in isolated valve surgery20, 21, 34, 35, 37, and 10 RCTs 
included a combination of CABG and valve surgery18, 19, 23–27, 32, 33, 36. The ischemic protocol (cycles × I/R) was 
3 × 5 min/5 min in 11 RCTs17–19, 22, 26, 28, 29, 32, 35–37, 4 × 5 min/5 min in 7 RCTs24, 25, 27, 30, 31, 33, 34, 3 × 10 min/10 min in 
2 RCTs20, 21, and 2 × 5 min/5 min in 1 RCT23. The upper limb was used in 11 RCTs17, 19, 22–29, 32, 35, the lower limb in 
3 RCTs18, 20, 37, the thigh in 6 RCTs21, 30, 31, 33, 34, 36, the combined of upper limb and thigh in 1 RCT23. The incidence 
of AKI was reported in 17 RCTs17–27, 31–36 (AKI stage I in 11 RCTs17–19, 22–27, 32, 36), the need for RRT in 19 RCTs17–20, 
22–33, 35–37, mortality in 19 RCTs17–19, 21–36, MV duration in 13 RCTs17, 20–22, 26–29, 31–35, ICU stay in 16 RCTs17, 20–23, 25–29, 
31, 33–37, and hospital length of stay (LOS) in 16 RCTs17–23, 25–28, 31, 33, 34, 36, 37. 19 RCTs17–21, 23–28, 30–37 had a Jadad score 
of more than 3. Further details of RCTs characteristics and the RIPC protocol used in each RCT are provided in 
Tables 1 and 2.
Effect of RIPC on the incidence of AKI, RRT, and Mortality. AKI was reported in 6054 study subjects, 
and the overall incidence was 25% (707/3017 in RIPC group, 777/3037 in control group). Postoperative inci-
dence of AKI was significantly reduced by RIPC (17 RCTs; odds ratio (OR) = 0.79; 95% CI, 0.65 to 0.96; P = 0.02; 
I2 = 38%; Fig. 2A). There was no evidence of publication bias (Begg’s test P = 0.22; Egger’s test P = 0.32).
For AKI, stage I the overall incidence was 19% (372/2122 in RIPC group, 439/2152 in control group). RIPC 
significantly reduced the risk of AKI stage I (11 RCTs; OR = 0.65; 95% CI, 0.47 to 0.89; P = 0.007; I2 = 55%; 
Fig. 2B) with no significant publication bias (Begg’s test P = 0.19; Egger’s test P = 0.08). There was no difference in 
the incidence of AKI stage II or stage III between the 2 groups as shown in Table 3.
The RRT was reported in 6047 study subjects, and the overall incidence was 3% (89/3013 in RIPC group, 
94/3034 in control group). The risk of postoperative RRT was not lowered in the RIPC group (19 RCTs; OR = 0.92; 
95% CI, 0.58 to 1.45; P = 0.71; I2 = 37%; Table 3).
The 30-day and 1-year mortality data were available in 4152 and 2166 patients and the mortality rates were 
1.5% and 5% respectively. There was no significant difference between the RIPC group and the control group for 
both these endpoints as shown in Table 3.
Effect of RIPC on MV duration, ICU stay, and hospital LOS. RIPC significantly shortened MV dura-
tion by 0.77 hours (13 RCTs; 95% CI, −1.32 to −0.23 hours; P = 0.005; I2 = 57%), and there was a trend towards 
reduced ICU stay by 0.23 days (16 RCTs; 95% CI, −0.49 to 0.02 days; P = 0.07; I2 = 96%) (Fig. 3). However, RIPC 
did not affect hospital LOS (16 RCTs; −0.01 days, 95% CI, −0.28 to 0.25 days; P = 0.92; I2 = 45%; Table 4).
Meta-regression and Subgroup analyses for Potential Sources of Heterogeneity. Age, male, 
previous myocardial infarction (MI), diabetes, hypertension, dyslipidemia, renal dysfunction, cardiopulmonary 
bypass duration, baseline left ventricular ejection fraction, complex surgery, CABG, use of volatile anesthesia, 
aspirin, angiotensin-converting enzyme inhibitors, beta-blockers, and statins, cumulative duration of precondi-
tioned ischemia, and additive ischemia were included in the random-effect univariate meta-regression analyses 
Figure 1. Screening and selection process of eligible RCTs for inclusion in this meta-analysis according to 
PRISM.
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for AKI stage I. The major sources of heterogeneity were age (coefficient = 0.06; P = 0.01; adjusted R2 = 0.86), 
hypertension (coefficient = 0.02; P = 0.09; adjusted R2 = 0.49), additive ischemia (coefficient = 0.04; P = 0.02; 
adjusted R2 = 0.93), and complex surgery (coefficient = 0.02; P = 0.03; adjusted R2 = 0.81) as shown in Table 4. 
Subsequent multivariate analyses showed that age (coefficient = 0.06; P = 0.01) and complex surgery (coeffi-
cient = 0.02; P = 0.03) remained significantly associated with AKI stage I, as shown in the meta-regression plots 
in Fig. 4 and Table 4. There was a relative reduction in the estimated effect size by 0.06 (natural transformation of 
OR) per 1-year increase in age and by 0.20 (natural log transformation of OR) per 10% increase in the proportion 
of complex surgery for AKI stage I by RIPC.
Subgroup analyses showed that RCTs with a mean age of <66 years old had less risk of AKI stage I than those 
with a mean age of ≥66 years old [OR: 0.37 versus 0.95, P < 0.001 for subgroup difference; Table 4]. Furthermore, 
RCTs with the proportion of complex surgery being <25% had significantly less AKI stage I than those with the 
proportion of complex surgery being ≥25% [OR: 0.43 versus 0.78; P = 0.005 for subgroup difference; Table 4].
Study Country Surgery
Pts. No. 
RIPC vs Ctrl
RIC protocol
RIC initiation 
to CPB
Placebo 
Control
Renal 
Endpoints
Baseline 
Creatinine 
level (mg/dl)
AKI 
Definition F-up
Jadad 
scoreCycles × I/R Cuff pressure
Rahman17 UK CABG (On) 42 vs 38
3 × 5 min/5 min at 
upper limb 200 mmHg 74 mins Yes
AKI, RRT, 
Mortality 1.10
SCr↑ 
>0.5 mg/dl 30 d 5
Thielmann28 German CABG (On) 27 vs 26
3 × 5 min/5 min at 
upper limb
Venugopal19 UK Combined 38 vs 40 3 × 5 min/5 min at upper limb 200 mmHg <45~60 mins Yes
AKI, RRT, 
Mortality 0.95 AKIN 30 d 4
Zimmerman18 USA Combined 59 vs 59 3 × 5 min/5 min at thigh 200 mmHg N.A No
AKI, RRT, 
Mortality 0.94 AKIN In-hospital 5
Choi20 Korea Valve 38 vs 38 3 × 10 min/10 min at thigh 250 mmHg >70 mins Yes AKI, RRT 0.915 AKIN In-hospital 5
Lomivorotov29 Russian CABG (On) 40 vs 40
3 × 5 min/5 min at 
upper limb 200 mmHg 30~50 mins Yes RRT N.A RRT In-hospital 1
Lucchinetti30 Canada CABG (On) 27 vs 28
4 × 5 min/5 min 
at thigh 300 mmHg N.A Yes RRT 1.01 RRT 6 mon 5
Hong31 Korea CABG (Off) 35 va 35
4 × 5 min/5 min 
at thigh 200 mmHg 18 mins Yes
RRT, 
Mortality 1.10 RRT 30 d 3
Kim21 Korea Valve 27 vs 27 3 × 10 min/10 min at thigh 250 mmHg
Pre- plus Post-
CPB Yes
AKI, RRT, 
Mortality N.A AKIN In-hospital 5
Young32 New Zealand Combined 48 vs 48
3 × 5 min/5 min at 
upper limb 200 mmHg N.A Yes
AKI, RRT, 
Mortality 1.10 RIFLE 30 d 5
Gallagher22 UK CABG 43 vs 43 3 × 5 min/5 min at upper limb 50 mmHg > SBP N.A Yes
AKI, RRT, 
Mortality 1.37 AKIN 30 d 2
Candilio23 UK Combined 57 vs 54
2 × 5 min/5 min 
at upper limb and 
thigh
200 mmHg <45 mins Yes AKI, RRT N.A AKIN In-hospital 5
Hong33 Korea Combined 644 vs 636 4 × 5 min/5 min at thigh 200 mmHg N.A Yes AKI N.A AKIN In-hospital 5
Hu34 China Valve 101 vs 100 4 × 5 min/5 min at thigh 600 mmHg Post-CPB Yes
AKI, 
Mortality 0.83 AKIN In-hospital 4
Pinaud35 France Valve 50 vs 49 3 × 5 min/5 min at upper limb 200 mmHg 91 mins Yes AKI, RRT N.A AKIN In-hospital 3
Hausenloy25 UK Combined 749 vs 772 4 × 5 min/5 min at upper limb 200 mmHg 105 min Yes
AKI, RRT, 
Mortality N.A KDIGO In-hospital 5
Zarbock26 German Combined 120 vs 120 3 × 5 min/5 min at upper limb
200 mmHg or 
50 mmHg > SBP N.A Yes
AKI, RRT, 
Mortality 1.15 KDIGO In-hospital 5
Meybohm24 German Combined 692 vs 693 4 × 5 min/5 min at upper limb
≥200 mmHg or 
15 mmHg > SBP N.A Yes
RRT, 
Mortality N.A RIFLE In-hospital 5
Cao37 China Valve 30 vs 30 3 × 5 min/5 min at lower limb 200 mmHg N.A Yes RRT N.A RRT In-hospital 3
Walsh36 Canada/US/India/China Combined 128 vs 130
3 × 5 min/5 min 
at thing 300 mmHg N.A Yes
AKI, RRT, 
Mortality 1.07 AKIN 6 mon 5
Kim27 Korea Combined 80 vs 80 4 × 5 min/5 min at upper limb 200 mmHg 29.4 h Yes
AKI, RRT, 
Mortality 0.9 AKIN In-hospital 5
Table 1. Study design in all included RCTs. Note: RCT, randomized controlled trials; CABG, coronary artery 
bypass graft; I/R, ischemia/reperfusion; SBP, systolic blood pressure; atm, atmosphere; AKI, acute kidney 
injury; RRT, renal replacement treatment; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; 
N.A, not available; AKIN, Acute Kidney Injury Network; RIFLE, Risk, Injury, Failure, Loss of renal function 
and End-stage renal disease; KDIGO, Kidney Disease: Improving Global Outcomes; RIPC, remote ischemic 
preconditioning; Ctrl, control.
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Substudy Age
Male 
(%)
Pre-MI 
(%) DM (%) HT (%)
Dyslipidemia 
(%)
Renal 
dysfunction 
(%)
CPB 
duration 
(min)
Baseline LVEF 
(%)
Complex 
Surgery 
(%)
CABG 
(%)
Volatile 
Anesthetic 
(%)
Aspirin 
(%)
ACEI 
(%)
β-blockers 
(%)
Statins 
(%)
Rahman17 64.0 88.5 0.0 0.0 59.3 74.1 N.A 98.0 60.1 0.0 100.0 98.1 88.3 64.8 80.9 90.7
Thielmann28 63.7 85.0 37.7 0.0 92.5 84.9 N.A 109.5 1.5(<35%) 0.0 100.0 100.0 83.0 64.2 75.5 64.2
Venugopal19 65.0 82.0 23.0 0.0 65.4 75.6 N.A 85.4 1.0(<35%) 14.1 96.0 61.5 66.7 65.4 55.0 79.5
Zimmerman18 63.5 68.6 N.A 22.5 47.0 N.A 16.1(eGFR<60) 114 10.2(<35%) 11.0 40.0 100.0 N.A 14.0 N.A N.A
Choi20 58.5 39.5 23.5 7.0 9.0 N.A 11.0(eGFR<60) 138.5 61.5 23.5 0.0 100.0 N.A 44.7 20.0 7.9
Lomivorotov29 57.3 96.1 N.A 0.0 N.A N.A N.A 64.5 59.0 0.0 100.0 100.0 N.A 56.6 86.8 N.A
Lucchinetti30 60.5 91.0 41.8 0.0 70.9 85.5 N.A 101.0 52.0 0.0 100.0 100.0 N.A 51.0 91.0 96.4
Hong31 64.7 72.9 N.A 35.7 68.6 17.1 0.0 54.0 0.0(<30.0%) 0.0 100.0 0.0 94.3 54.3 64.3 72.9
Kim21 57.5 55.6 N.A 13.0 33.3 N.A 0.0 127.5 64.5 48.1 0.0 N.A N.A 11.1 22.2 5.6
Young32 66.4 62.5 27.8 N.A N.A 60.4 N.A 111.1 2.0(<30.0%) 31.3 57.3 100.0 N.A 52.1 66.7 60.4
Gallagher22 70.8 80.2 52.3 64.0 82.6 77.9 N.A 94.0 52.0/10.5(<35%) 5.8 96.5 87.2 96.5 79.1 35.0 N.A
Candilio23 65.5 78.1 28.7 29.2 78.8 74.2 0.0 93.2 4.5(<30%) 11.8 62.4 96.1 77.5 66.3 62.9 80.9
Hong33 60.8 61.3 7.3 30.2 48.6 53.8 3.1 159.7 57.0 19.7 50.8 N.A 48.3 39.1 42.7 N.A
Hu34 47.1 37.8 0.0 0.0 0.0 N.A 0.0 81.3 0.0(<35%) 39.3 0.0 100.0 N.A N.A N.A N.A
Pinaud35 74.4 51.5 0.0 14.1 77.8 53.5 N.A 81.4 65.6 0.0 0.0 100.0 18.2 20.2 28.3 40.4
Hausenloy25 76.2 70.8 39.5 25.7 74.5 69.8 0.0 70.0 11.6(<35%) 50.2 N.A 40.2 78.4 60.3 64.0 79.7
Zarbock26 70.4 62.9 0.0 37.5 96.7 N.A 30.9 118.0 15.0(<35%) 46.3 N.A 100.0 59.6 60.0 60.8 68.8
Meybohm24 66.0 74.2 28.9 24.8 N.A N.A 11.2 115.0 0.0(<35%) 27.2 N.A 2.7 N.A 52.7 63.2 65.5
Cao37 53.0 48.3 N.A 0.0 N.A N.A N.A 115.0 51.0 N.A N.A N.A 0.0 N.A N.A 0.0
Walsh36 72.2 58.5 29.4 30.6 N.A N.A 3.9 137.6 N.A 32.2 57.0 83.7 N.A N.A N.A N.A
Kim27 62.3 53.1 N.A 0.0 34.4 N.A 0.0 230.9 58.5 36.3 6.3 0.0 N.A N.A N.A N.A
Table 2. Patient characteristics in all included randomized trials. Note: Pre-MI, previous myocardial infarction; 
DM, diabetes mellitus; HT, hypertension; CPB, cardiopulmonary bypass; eGFR, estimated glomerular filtration 
rate; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass graft; ACEI, angiotensin-converting 
enzyme inhibitor; N.A, not available.
Endpoints References RIPC Control
Pts with 
complete 
data OR (95% CI) WMD (95% CI)
P 
value
AKI 17–27, 31–36 707/3017(23.4%) 777/3037(25.6%) 96.06% 0.79(0.65, 0.96) / 0.02
AKI stage I 17–19, 22–27, 32, 36 372/2122(17.5%) 439/2152(20.4%) 67.79% 0.65(0.47, 0.89) / 0.007
AKI stage II 18, 19, 22–27, 32, 36 105/2046(5.1%) 100/2074(4.8%) 65.38% 1.07(0.81,1.42) / 0.64
AKI stage III
17–20, 
22–33, 
35–37
89/3013(3.0%) 94/3034(3.1%) 95.95% 0.92(0.58,1.45) / 0.71
RRT
17–20, 
22–33, 
35–37
89/3013(3.0%) 94/3034(3.1%) 95.95% 0.92(0.58,1.45) / 0.71
Mortality (30-day)
17–19, 
21, 22, 24, 
26–29, 
31–35
31/2079(1.5%) 32/2073(1.5%) 65.89% 0.96(0.58, 1.61) / 0.89
Mortality (<1 year) 17, 23, 25, 30, 36 60/1069(5.6%) 48/1097(4.4%) 34.37% 1.19(0.62, 2.29) / 0.60
MV duration
17, 20–22, 
26–29, 
31–35
1330 1317 42.00% / −0.77(−1.32, −0.23) 0.005
ICU stay
17, 20–23, 
25–29, 31, 
33–37
2277 2293 72.52% / −0.23(−0.49, 0.02) 0.07
Hospital LOS
17–23, 
25–28, 31, 
33, 34, 36, 37
2284 2303 72.79% / −0.01(−0.28, 0.25) 0.92
Table 3. Pooled analysis of the postoperative primary and second endpoints. Notes: AKI, acute kidney injury; 
RRT, renal replacement treatment; MV duration, mechanic ventilation duration; ICU stay, intensive care unit 
stay; Hospital LOS, hospital length of stay; Pts, patients; OR, odds ratio. WMD, weighted mean difference; CI, 
confidence interval; RIPC, remote ischemic preconditioning.
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Discussion
In this meta-analysis of 21 RCTs involving 6302 adult patients undergoing cardiac surgery, we found that RIPC 
reduced the incidence of AKI. In addition, RIPC also shortened MV duration and there was a trend towards 
shorter ICU stay, but heterogeneity among the included RCTs was substantial for the latter. RIPC was more effec-
tive at reducing AKI stage I in RCTs with younger patients (<66 years old) and in those RCTs with less complex 
cardiac surgery (<25%). However, RIPC did not affect AKI stage II and III/requirement for RRT, hospital length 
of stay, and mortality.
Post-operative AKI in adult cardiac surgery is a common complication, occurring in up to a third of surgical 
cases4, 38, 39. Even minor increase in postoperative serum creatinine level following cardiac surgery has been shown 
to be associated with increased MV duration40, prolonged ICU stay41, and the risk of short-term mortality2, 41, 42. 
Although AKI can occur due to numerous reasons and the underlying mechanisms remain unclear, acute tubular 
necrosis has been implicated as being the predominant pathology43. There is currently no effective renoprotective 
strategy to reduce the burden of AKI in this setting44. Several RCTs have investigated the renoprotective effect of 
Figure 2. Forest plot of the effect on RIPC on (A) AKI and (B) AKI stage I.
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RIPC in patients undergoing cardiac surgery but with conflicting results. To minimize heterogeneity due to trial 
design and patient selection, our study only included RCTs involving adult cardiac surgery, but not in combina-
tion with major vascular surgery45, 46, pediatric cardiac surgery46, 47, percutaneous coronary intervention47, 48, or 
organ transplantation47.
We found that RIPC reduced the incidence of AKI stage I and MV duration, and there was a trend towards 
shorter ICU stay. Our findings are consistent with the RCT by Zarbock et al.26, which was specifically designed 
and powered to look at the effect of RIPC on AKI as the primary endpoint in 240 patients. Of note, they only 
included patients at high risk of AKI. Furthermore, they used volatile anesthesia instead of propofol, the latter of 
which may potentially attenuate the effect of RIPC49, 50. They showed a 15% and 10% absolute risk reduction in 
the incidence of AKI and the need for RRT, respectively. RIPC also reduced the duration of stay in ICU but there 
was no difference in overall hospital length of stay26.
The risk of death is proportional to the severity of AKI, with the highest rate occurring in patients requir-
ing RRT following adult cardiac surgery4, 51, 52. In our analysis, the incidence of RRT was 3.1% and the 30-day 
mortality was only 1.5% (4152 patients), many of whom presented with normal preoperative serum creatinine 
Figure 3. Forest plot of the effect on RIPC on (A) MV duration and (B) hospital length of stay.
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level. RIPC did not affect the need for RRT or mortality in our analysis. Thielmann et al.53 randomized 329 
patients undergoing CABG and obtained similar findings to our study for 30-day mortality. However, they found 
that RIPC reduced 1-year mortality and the result remained significant after 4-year follow-up. Therefore, longer 
follow-up duration should be considered in future RCTs to see a benefit in mortality.
Translating renoprotective strategies that have shown promise in young and healthy animals into the clinical 
population with various co-morbidities and/or confounders (such as age54, 55, surgical complexity56, and previous 
MI57) has proven to be challenging. Our meta-regression analysis showed that age was negatively correlated with 
the reduction in AKI stage I by RIPC. Likewise, the proportion of complex surgery was negatively correlated 
with the reduction in AKI stage I. Based on the findings from our study and that of Zarbock et al.26, whether 
pre-selecting a younger cohort of patients who are at risk of AKI, undergoing non-complex surgery using volatile 
anesthesia may more likely show a significant reduction in all stages of AKI by RIPC and eventually improve 
clinical outcomes, remain to be assessed in future, adequately powered RCTs.
There are several limitations in our study. Firstly, we were unable to access the patient-level data. Therefore, 
the potential influences of co-morbidities (diabetes19, baseline left ventricular ejection fraction57, and interval 
between coronary angiography and surgery58) and cardiovascular medications (such as volatile anesthetics59 and 
statins60) may have been underestimated. Secondly, AKI was based on different definitions such as AKI Network 
classification (AKIN), Risk/Injury/Failure/Loss/End-stage (RIFLE) criteria or the Kidney Disease: Improving 
global Outcomes (KDIGO) classification61, 62, and the patient selection, type of surgery and RIPC protocol used 
were different and may have contributed to the heterogeneity. Thirdly, although we included several recently pub-
lished large RCTs, the sample size was still relatively small to be adequately powered for hard clinical outcomes. 
Last but not least, only 11 RCTs qualified for the meta-regression analysis and therefore the conclusions may not 
be robust but hypothesis generating.
In conclusion, the available evidence from the present meta-analysis indicates that RIPC reduces the incidence 
of AKI in adults undergoing cardiac surgery and this benefit was more pronounced in younger patients under-
going non-complex cardiac surgery. RIPC may also shorten MV duration, and length of stay in ICU, and this 
warrants further investigation in future RCTs tailored for those most likely to benefit.
Methods
Search strategy and study criteria. This meta-analysis was performed according to the PRISMA state-
ment63 as shown in the flow chart in Fig. 1. We did a systematic search in PubMed, EMBase, and Cochrane 
Library (up to November 2016) using keywords “remote ischemic preconditioning”, “remote ischaemic precon-
ditioning”, “ischemic preconditioning”, “cardiac surgery”, “heart surgery”, “kidney”, and “renal”. Furthermore, 
editorials and references from included RCTs were manually searched. RCTs published in English and involving 
adult patients were included. Exclusion criteria were: (1) pediatric cardiac surgery; (2) studies not reporting acute 
kidney injury (AKI) and RRT during hospitalization.
Variables Endpoint
No. 
RCTs Covariate
Coeff./
OR/WMD 95% CI P Value
Univariate Coeff. Adjusted R2
Age (years) AKI stage I 11 / 0.06 0.02~0.11 0.01 0.86
HT (%) AKI stage I 8 / 0.02 −0.004~0.04 0.09 0.49
Additive 
ischemia (%) AKI stage I 11 / 0.04 0.007~0.07 0.02 0.93
Complex surgery 
(%) AKI stage I 11 / 0.02 0.002~0.03 0.03 0.81
Multivariate Coeff. Adjusted R2
Age
AKI stage I 9 Previous MI (%) 0.05 −0.01~0.10 0.09 1.00
AKI stage I 10 Diabetes (%) 0.06 0.005~0.12 0.04 0.81
AKI stage I 8 HT (%) 0.07 0.01~0.13 0.03 1.00
Complex surgery 
(%)
AKI stage I 9 Previous MI (%) 0.02 −0.001~0.03 0.06 1.00
AKI stage I 10 Diabetes (%) 0.02 0.003~0.033 0.03 0.95
Subgroup I2 PDifferenceValue
OR
1. Age (years)
AKI stage I
11 / 0.65 0.47~−0.89 0.007 54.70%
<0.00001  ≥66.0 6 / 0.95 0.80~1.13 0.58 0.00%
  <66.0 5 / 0.37 0.24~0.58 <0.00001 0.00%
2.  Complex 
surgery (%)
AKI stage I
11 / 0.65 0.47~−0.89 0.007 54.70%
0.005  ≥25% 5 / 0.78 0.57~1.08 0.13 54.00%
  <25% 6 / 0.43 0.27~0.71 0.001 0.00%
Table 4. Meta-regression and Subgroup analyses for the potential sources of heterogeneity. Note: AKI, acute 
kidney injury; ICU stay, intensive care unit stay; HT, hypertension; previous MI, previous myocardial infarction; 
LVEF, left ventricular ejection fraction; Coeff., coefficient; WMD, weighted mean difference; CI, Confidence 
Interval.
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Literature review and data extraction. The literature review and data extraction were independently 
completed by two investigators (J.G. and Y.Z.). Any disagreements were resolved by consensus. Quality assess-
ment was performed according to Jadad score: randomization; blinding; withdrawals and dropouts (a possible 
score between 0 and 5). Trials with a score of more than 3 were considered as being of high-quality64. Data 
extraction included patient’s age, male gender, history of MI, diabetes, hypertension, dyslipidemia, renal dys-
function, CPB duration, baseline LVEF, type of surgery (complex surgery defined as a combination of valve, 
CABG, or major vascular surgery), usage of volatile anesthesia, aspirin, angiotensin converting enzyme inhibi-
tors, beta-blockers and statins. Cumulative duration of preconditioned ischemia was calculated multiplying the 
number of cycles by the ischemic duration (for example, 3*5 min = 15 min for preconditioning with 3 × 5 min 
ischemia/5 min reperfusion). Additive ischemia65 was calculated using cumulative duration of preconditioned 
ischemia relative to the CPB duration.
Postoperative Outcomes. The primary endpoints were incidence of AKI as a whole and AKI stage I–III 
individually, and the definition used by each RCT (AKIN, RIFLE, or KDIGO criteria61) was used for this study.
The secondary endpoint included RRT (defined as dialysis or hemofiltration), mechanic ventilation (MV) 
duration, intensive care unit (ICU) stay, and hospital length of stay (LOS).
Statistical analysis. For dichotomous outcomes (reported as incidence), we calculated OR with 95% CI. 
For continuous outcomes (MV duration, duration of stay in ICU and hospital length of stay) reported as mean 
and standard deviation, the WMD for the pooled estimates with 95% CI were calculated. For RCTs reporting 
median and interquartile range, or median and range, the method described by Hozo et al.66 was used to convert 
to mean and standard deviation. Random-effect model was used in view of differences in patient selection and the 
RIPC protocol used among the RCTs. Publication bias was assessed by Begg’s test and Egger’s test. Heterogeneity 
among RCTs was quantified using I2 statistics with I2 of 0–40%, 30–60%, 50–90% and 75–100% considered as 
low, moderate, substantial and considerable heterogeneity, respectively, as defined by the Cochrane handbook of 
systematic reviews67 and moderate heterogeneity was considered acceptable. Meta-regression (P < 0.1) and sub-
group analysis were conducted for positive results to explore the potential sources of heterogeneity68. To reduce 
Figure 4. Meta-regression plots on the incidence of AKI stage I against (A) age and (B) proportion of complex 
surgery.
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the possibility of over-fitting in the multivariate regression model, at least four studies or sub-studies were set for 
the identification of each influential factor69, 70. P < 0.05 (2-sided) was considered to be statistically significant. All 
statistical analyses were performed in Stata (version 9.0; Stata Corporation, College Station, TX).
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